{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:09:53Z","timestamp":1787026193752,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A well-designed, protocol-driven randomized controlled trial (RCT) has demonstrated the efficacy of fluticasone furoate-umeclidinium-vilanterol (FF-UMEC-VI) in patients with asthma, but there is a lack of real-world data that can be used to translate the results of the RCT into clinical practice. This study evaluated the efficacy of switching the therapy from inhaled corticosteroid-long-acting \u03b22-agonists (ICS-LABAs) to FF-UMEC-VI at the equivalent corticosteroid dose in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, three-month, open-label, parallel-group, switching therapy trial was performed in patients with symptomatic asthma under routine management. Patients receiving low-to-medium doses of ICS-LABAs were switched to FF-UMEC-VI (100\u201362.5\u201325\u2005\u00b5g, once daily) (T100 group), and patients receiving a high dose of ICS-LABAs were switched to FF-UMEC-VI (200\u201362.5\u201325\u2005\u00b5g, once daily) (T200 group). The primary outcome was the change from baseline in forced expiratory volume in 1\u2005s (\u0394FEV1) at week 12, and the secondary outcomes were the improvement in fractional exhaled nitric oxide (FeNO), the asthma symptoms evaluated using the asthma control test (ACT), and the cough severity evaluated using the visual analog scale (VAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-five patients were switched to T100, and thirty patients were switched to T200. The \u0394FEV1 was improved by more than 100\u2005ml at 8 weeks after switching in both groups (T100, 110.4\u2009\u00b1\u200939.8\u2005ml; T200, 117.1\u2009\u00b1\u200939.8\u2005ml) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05) but slightly decreased at 12 weeks. ACT also improved by more than 3 points at 8 weeks after switching and was maintained to 12 weeks in both groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Patients with ACT scores of &amp;lt;20 (i.e., poor control) before switching showed a greater improvement in the symptoms during T100 therapy, and 92% had reached an ACT score of &amp;gt;20 (i.e., good control). FeNO in the T100 group was decreased at 4 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Cough VAS also significantly decreased but did not reach a minimal clinically important difference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with symptomatic asthma showing insufficient control, an improvement in the asthma symptoms was observed after switching to FF-UMEC-VI at the equivalent corticosteroid dose, accompanied by an improvement in FEV1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2025.1537501","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:18:49Z","timestamp":1742181529000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control study"],"prefix":"10.3389","volume":"6","author":[{"given":"Yoshitomo","family":"Kushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Chibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takemasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meitetsu","family":"Masawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinna","family":"Tei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Yukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"B1","article-title":"Global Initiative for Asthma","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.resinv.2021.02.003","article-title":"The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients","volume":"59","author":"Gon","year":"2021","journal-title":"Respir Investig"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41533-023-00336-9","article-title":"Suboptimally controlled asthma in patients treated with inhaled ICS\/LABA: prevalence, risk factors, and outcomes","volume":"33","author":"Zhang","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"106915","DOI":"10.1016\/j.rmed.2022.106915","article-title":"The 5T approach in asthma: triple therapy targeting treatable traits","volume":"200","author":"Cazzola","year":"2022","journal-title":"Respir Med"},{"key":"B6","article-title":"Global Initiative for Asthma","year":"2022"},{"key":"B7","article-title":"Global Initiative for Asthma","year":"2023"},{"key":"B8","article-title":"Global Initiative for Asthma","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1080\/03007995.2021.1944849","article-title":"Efficacy and safety of once-daily, single-inhaler fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study","volume":"37","author":"Nakamura","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jaip.2024.01.039","article-title":"Baseline characteristics and ICS\/LAMA\/LABA response in asthma: analyses from the CAPTAIN study","volume":"12","author":"Boulet","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.jaip.2024.05.019","article-title":"Characterization of moderate and severe asthma exacerbations in the CAPTAIN study","volume":"12","author":"Oppenheimer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2147\/jaa.S424055","article-title":"Real-world study of single-inhaler triple therapy with fluticasone furoate\/umeclidinium\/vilanterol on asthma control in the US","volume":"16","author":"Bogart","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaip.2022.02.026","article-title":"Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases","volume":"10","author":"Canonica","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2006.065144","article-title":"Recommendations for the management of cough in adults","volume":"61","author":"Morice","year":"2006","journal-title":"Thorax"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ggi.14057","article-title":"Use of dementia assessment sheet for community-based integrated care system 8-items (DASC-8) for the screening of frailty and components of comprehensive geriatric assessment","volume":"20","author":"Toyoshima","year":"2020","journal-title":"Geriatr Gerontol Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/jaa.S223093","article-title":"Once-daily fluticasone furoate\/vilanterol combination versus twice-daily budesonide\/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial","volume":"12","author":"Furuhashi","year":"2019","journal-title":"J Asthma Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/s0140-6736(17)32397-8","article-title":"Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial","volume":"390","author":"Woodcock","year":"2017","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.21037\/jtd-19-3913","article-title":"Real-life effectiveness of fluticasone furoate\/vilanterol after switching from fluticasone\/salmeterol or budesonide\/formoterol therapy in patients with symptomatic asthma: relvar ellipta for real asthma control study (RERACS study)","volume":"12","author":"Shimizu","year":"2020","journal-title":"J Thorac Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.alit.2019.04.009","article-title":"Impact of airflow obstruction on long-term mortality in patients with asthma in Japan","volume":"68","author":"Okayama","year":"2019","journal-title":"Allergol Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12931-021-01864-z","article-title":"Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma","volume":"22","author":"Tupper","year":"2021","journal-title":"Respir Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jaci.2011.04.039","article-title":"Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial","volume":"128","author":"Kerstjens","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/jaa.S401505","article-title":"The efficacy and safety of first-line single-inhaler triple versus dual therapy in controller-na\u00efve and symptomatic adults with asthma: a preliminary retrospective cohort study","volume":"16","author":"Fujiki","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12931-022-02114-6","article-title":"Effects of treatment with montelukast alone, budesonide\/formoterol alone and a combination of both in cough variant asthma","volume":"23","author":"Yi","year":"2022","journal-title":"Respir Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.jaip.2019.02.023","article-title":"ELLIPTA Dry powder versus metered-dose inhalers in an optimized clinical trial setting","volume":"7","author":"Kerwin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"publisher","first-page":"170055","DOI":"10.1183\/16000617.0055-2017","article-title":"Inhaler technique: does age matter? A systematic review","volume":"26","author":"Barbara","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaci.2006.10.035","article-title":"The predicting response to inhaled corticosteroid efficacy (PRICE) trial","volume":"119","author":"Martin","year":"2007","journal-title":"J Allergy Clin Immunol"}],"updated-by":[{"DOI":"10.3389\/falgy.2025.1683768","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000}}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1537501\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:09:10Z","timestamp":1758751750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1537501\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":28,"alternative-id":["10.3389\/falgy.2025.1537501"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1537501","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"article-number":"1537501"}}